Doesn’t the marketing of Authorized Generics offer consumers benefits during the 180-day exclusivity period while preserving the value of patent challenges?
Yes. The introduction of Authorized Generics in the marketplace lowers prices during the 180-day exclusivity period, and the presence of Authorized Generics does not eliminate the economic incentive for challenging patents. As stated before, if an Authorized Generic is available during the 180-day period, the patent-challenging generic still has a return on investment of 470%.10 There is no evidence that patent challenges are discouraged.
Related Questions
- Will competition from Authorized Generics further drive down the price for off-patent pharmaceuticals, giving consumers alternatives to purchasing their drugs from foreign suppliers?
- Hasn’t legislation been recently introduced to prohibit Authorized Generics during the 180-day exclusivity period?
- What benefits do generics offer?
